Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.3K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.3K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.4K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.4K
Drug Therapy01:28

Drug Therapy

450
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
450
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An evaluation of aripiprazole long-acting injectable monthly and bimonthly in the maintenance treatment of bipolar I disorder.

Therapeutic delivery·2026
Same author

Investigating the effects of antidepressants on measures of insulin resistance in major depressive disorder: A systematic review.

Journal of affective disorders·2026
Same author

Ketamine for the Treatment of Obsessive-Compulsive Disorder (OCD): A Systematic Review on Efficacy and Tolerability.

Clinical neuropharmacology·2026
Same author

Nephroprotective Effects of GLP-1 Receptor Agonists in Lithium-Treated Patients: A Multinational Cohort Study Using the TriNetX Network.

CNS spectrums·2026
Same author

Lithium and long-term cognitive outcomes in bipolar disorder and early dementia: a systematic review.

CNS spectrums·2026
Same author

The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression.

Clinical pharmacology and therapeutics·2026
Same journal

The Clinical Threshold for Treatment in Psychiatry.

JAMA psychiatry·2026
Same journal

Semaglutide in Schizophrenia-A Top Clinical Trial.

JAMA psychiatry·2026
Same journal

Adolescent Peers' Diagnoses and Genetic Predispositions and Subsequent Risk of Mental Disorders.

JAMA psychiatry·2026
Same journal

Use and Misuse of GLP-1 Receptor Agonists Among People With Eating Disorders.

JAMA psychiatry·2026
Same journal

Connectivity- vs Scalp-Based Targeting of Accelerated Transcranial Magnetic Stimulation for Depression: A Randomized Clinical Trial.

JAMA psychiatry·2026
Same journal

Neurometabolites and Antipsychotic Response in Psychosis: A Mega-Analysis.

JAMA psychiatry·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.9K

Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.

Roger S McIntyre1,2,3, Stephen M Stahl4, Sung Ryul Shim5

  • 1Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.

JAMA Psychiatry
|May 6, 2026
PubMed
Summary
This summary is machine-generated.

This study compared atypical antipsychotics for major depressive disorder (MDD). Lumateperone showed the highest efficacy, while all agents demonstrated varying acceptability, highlighting the need for individualized treatment in MDD.

More Related Videos

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.8K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K

Related Experiment Videos

Last Updated: May 7, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

31.9K
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.8K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Research

Background:

  • Many adults with major depressive disorder (MDD) do not achieve remission with standard antidepressants.
  • The US Food and Drug Administration (FDA) has approved five atypical antipsychotics as adjunctive treatments for MDD due to their proven efficacy and safety.

Conclusions:

  • Significant differences in efficacy and acceptability exist among adjunctive atypical antipsychotics for MDD.
  • Treatment decisions should simultaneously consider both efficacy and acceptability profiles.
  • Further research is needed to address the knowledge gap regarding the maintenance efficacy of these agents in MDD.